论文部分内容阅读
本文报告用CHOP方案治疗103例非何杰金氏淋巴瘤的经验。全部病例均经病理组织学证实,按工作分型属中、高度恶性者71％。除标准CHOP或CHOP—Bleo方案外,26例化疗后曾用局部放疗。化疗均在三疗程上,66％用药6疗程以上。 治疗结果:全组总缓解率90.7％,完全缓解率57.7％。74例初治病例总缓解率95.6％,完全缓解率60.3％。全组中位生存期(MST)22.5个月,获CR者MST36个月以上,未获CR者MST不足12个月。全组1年生存率66.7％,3年生存率36.4％。获CR者3年生存率约59％。主要毒副反应为消化道反应、白细胞降低及脱发,但多不严重,无致死性毒副反应发生。部份病例有心电图改变,但无心力衰竭发生。
This article reports the experience of treating 103 cases of non-Hodgkin’s lymphoma with CHOP regimen. All cases were confirmed by histopathology, according to the work of genotyping, 71% of highly malignant. In addition to the standard CHOP or CHOP-Bleo regimen, 26 cases had been treated with local radiotherapy after chemotherapy. Chemotherapy are three courses, 66% medication for more than 6 courses. Treatment outcome: The overall response rate was 90.7%, the complete remission rate was 57.7%. 74 cases of initial treatment of the total remission rate was 95.6%, complete remission rate of 60.3%. The median survival time (MST) of 22.5 months, CR patients were MST for more than 36 months, those with CR were less than 12 months MST. The overall 1-year survival rate was 66.7%, 3-year survival rate of 36.4%. CR patients were 3 years survival rate of about 59%. The main side effects of gastrointestinal reactions, leukopenia and hair loss, but not serious, no lethal side effects. Some cases have ECG changes, but no heart failure occurs.